Merck KgaA foresees meeting 2018 objectives and plans for 2022

pharmafile | October 13, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2018, 2022, Germany, Merck KGaA 

Speaking at its 2016 Capital Market Day about the progress it had made towards its 2018 objectives, CEO Stefan Oschmann and CFO Marcus Kuhnert were confident in their projections. “We firmly believe that we will meet the objectives we have set for 2018,” announced Stefan Oschmann. “We have focused our pharmaceutical pipeline and continuously developed it further.”

Merck are counting on their pharmaceutical pipeline and aims to gain approval of one medicine or one indication every year. They project to generate sales of €2 billion with products from their current pharmaceutical pipline. They have ruled out any major acquisitions of more than €500 million, unless divestments could be used to finance them.

Looking forward to 2022, the Merck Group plan to continue with plans to build on its current portfolio. “With our three strong and profitable businesses, we want to remain a leader at the forefront of scientific and technological progress,” said Merck CEO Stefan Oschmann, looking at growth and innovations in the coming years. This will include deals, such as the collaboration agreement with Transgene to explore the efficacy of combining their own avelumab with Transgene’s TG4001.

Ben Hargreaves

Related Content

Exscientia enters AI drug discovery collaboration with Merck KGaA

Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on …

mr058666-web

Merck KGaA’s cancer drug Bavencio gets EU approval

The EC has approved Merck KGaA’s BAVENCIO (avelumab) as monotherapy for the first-line maintenance treatment …

bel-n-garijo-large

Company veteran Belén Garijo named as Merck KGaA’s first-ever female CEO

German pharma firm Merck KGaA has taken the decision to appoint its first female Chief …

Latest content